Dexmethylphenidate HCl extended-release capsules

Phase 3Completed
0 views this week 0 watching Active
Interest: 40/100
40
Hype Score

Development Stage

Pre-clinical
Phase 1
Phase 2
4
Phase 3
5
Approved
Indication / Disease

ADHD, ADD

Conditions

ADHD, ADD

Trial Timeline

Feb 1, 2006 → Nov 1, 2006

About Dexmethylphenidate HCl extended-release capsules

Dexmethylphenidate HCl extended-release capsules is a phase 3 stage product being developed by Novartis for ADHD, ADD. The current trial status is completed. This product is registered under clinical trial identifier NCT00301236. Target conditions include ADHD, ADD.

What happened to similar drugs?

10 of 20 similar drugs in ADHD, ADD were approved

Approved (10) Terminated (3) Active (9)
atomoxetineEli LillyApproved
Strattera (atomoxetine)Eli LillyApproved
Atomoxetine + placeboEli LillyApproved
atomoxetine (Strattera)Eli LillyApproved
🔄dasotraline + PlaceboSumitomo PharmaPhase 3
🔄dasotraline 4mgSumitomo PharmaPhase 3

Hype Score Breakdown

Clinical
17
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT00301236Phase 3Completed

Competing Products

20 competing products in ADHD, ADD

See all competitors
ProductCompanyStageHype Score
atomoxetineEli LillyApproved
39
Strattera (atomoxetine)Eli LillyApproved
43
Atomoxetine + placeboEli LillyApproved
43
Atomoxetine Hydrochloride + placeboEli LillyApproved
43
atomoxetine (Strattera)Eli LillyApproved
43
Atomoxetine + stimulants (any approved ADHD medication)Eli LillyPre-clinical
26
dasotraline + PlaceboSumitomo PharmaPhase 3
40
dasotralineSumitomo PharmaPhase 1
29
dasotraline 4mgSumitomo PharmaPhase 3
40
AZD1446 + AZD1446 + AZD1446 + PlaceboAstraZenecaPhase 2
35
Placebo + AZD3480 + AZD3480AstraZenecaPhase 2
35
MK0249 + Concerta (methylphenidate) + PlaceboMerckPhase 2
35
Focalin XRNovartisPhase 3
40
Dex-Methylphenidate hydrochloride Extended Release (Focalin® XR) + PlaceboNovartisApproved
43
Methylphenidate hydrochlorideNovartisPhase 3
40
Focalin XRNovartisPhase 3
40
methylphenidate HCl ERCT + PlaceboPfizerApproved
35
methylphenidate HCl ERCTPfizerApproved
35
Very Low Dose Quillivant XR + Low Dose Quillivant XR + Moderate Dose Quillivant XRPfizerApproved
43
BrexpiprazoleLundbeckPhase 1
26